Emery Heidi, Evans Catrin, Jack Kathryn, Martello Elisa, Seripenah Princella, Aiyelabegan Fatima, Dhungana Surakshya, Joseph Titus, Koboto Dirontsho, Morling Joanne R, Stewart-Evans James, Wilson Emma, Leonardi-Bee Jo
Centre for Public Health and Epidemiology, School of Medicine, University of Nottingham, Nottingham, UK.
Nottingham Centre for Evidence Based Healthcare, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK.
J Viral Hepat. 2025 Feb;32(2):e14049. doi: 10.1111/jvh.14049.
The prevalence of viral hepatitis among people in prisons is higher than in the general population. Screening, treatment and vaccination programmes exist within prisons to reduce the incidence of hepatitis, although lower uptake has often been reported compared to similar programmes outside of prisons. We conducted a systematic review of qualitative evidence to explore the barriers and facilitators to hepatitis B and C reduction programmes in prisons from the perspectives of people in prison, custodial staff and prison healthcare staff. Comprehensive searches of five databases (to November 2023) yielded 28 studies for review inclusion. Four synthesised findings were identified: (i) accurate, up-to-date knowledge of viral hepatitis disease and treatment among people in prison and staff is a facilitator to programme uptake, particularly when imparted by a trusted source; (ii) personal subjective and relative views have a bearing on participation with the programme; (iii) social interactions and relationships both within the community of people in prison and between them and staff groups influence participation in the programmes; and (iv) the organisational structure of the prison and healthcare services within it affect programme participation. Based on these findings, we make recommendations for the adaptation of viral hepatitis programmes to individual custodial settings thereby improving equitable programme access and hepatitis B and C reduction in this complex environment.
监狱人群中病毒性肝炎的患病率高于普通人群。监狱内设有筛查、治疗和疫苗接种项目以降低肝炎发病率,不过与监狱外的类似项目相比,这些项目的参与率往往较低。我们对定性证据进行了系统综述,从囚犯、监管人员和监狱医护人员的角度探讨监狱中乙肝和丙肝防控项目的障碍与促进因素。对五个数据库(截至2023年11月)进行全面检索后,有28项研究被纳入综述。我们确定了四项综合研究结果:(i)囚犯和工作人员对病毒性肝炎疾病及治疗有准确、最新的了解是项目实施的促进因素,尤其是由可信来源提供相关信息时;(ii)个人主观和相对观点会影响对项目的参与;(iii)监狱内人群社区内部以及他们与工作人员群体之间的社会互动和关系会影响对项目的参与;(iv)监狱的组织结构及其内部的医疗服务会影响项目参与情况。基于这些发现,我们建议针对个别监管环境调整病毒性肝炎项目,从而在这个复杂环境中改善项目的公平可及性并降低乙肝和丙肝感染率。